Trial Profile
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2017
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Millennium
- 07 Feb 2017 Pooled results assessing pregnancy outcomes from six clinical studies and post marketing safety data published in the Alimentary Pharmacology and Therapeutics.
- 24 Apr 2014 Primary endpoint 'Immunological-response-rate' has been met.
- 24 Apr 2014 Results published in the Gut.